Emeryville, United States
Metagenomi Therapeutics, established in 2018, is redefining the genetic medicine landscape with its focus on curing diseases through innovative genome editing techniques. Their bold slogan, "Unlocking 4 billion years of microbial evolution to cure disease," underscores their mission.
At the heart of their operation lies a comprehensive metagenomics-derived genome editing toolbox, setting them apart in the Biotechnology, AI, and Machine Learning sectors. By exploring genomes from uncultivated organisms, Metagenomi is poised to develop therapeutic interventions with precision, targeting any gene in the human genome.
Headquartered in the United States, the company successfully secured a substantial $100.00M Series B investment on 05 January 2023. This funding round was led by prominent investors including Novo Holdings, Catalio Capital Management, Leaps by Bayer, Moderna, and Symbiosis LLC. These investments validate Metagenomi's potential to redefine therapeutic genome editing.
